Timing clarification: STERIS will release fiscal first-quarter results after the U.S. market closes today, August 5, 2026. The earnings call is scheduled for 9:00 a.m. ET on August 6, 2026. (fidelity.com)
The central question is not whether STERIS can produce another quarter of mid- to high-single-digit organic growth. It is whether the company can protect margins while Applied Sterilization Technologies (“AST”) works through tougher comparisons and customer inventory adjustments.
STERIS entered fiscal 2027 guiding to:
That outlook looks achievable, but expectations have risen. STE traded around $233 immediately before the report, equivalent to roughly 20.8 times the $11.20 midpoint of management’s FY2027 adjusted-EPS guidance. The stock has also recovered substantially from the low-$200s around the May earnings report. (marketbeat.com)
Accordingly, a small EPS beat with an unchanged outlook may be received as merely “in line.” The more important signals will be organic growth quality, AST volumes and management’s confidence in second-half acceleration.
Public estimate aggregators vary modestly, but expectations generally cluster around:
| Metric | Approximate expectation | Fiscal Q1 2026 |
|---|---|---|
| Revenue | $1.50–$1.51 billion | $1.391 billion |
| Adjusted EPS | $2.49–$2.53 | $2.34 |
| Implied revenue growth | ~8% | 9% reported |
| Implied adjusted-EPS growth | ~7%–8% | 15% |
Public sources show EPS estimates between approximately $2.49 and $2.53 and revenue near $1.5 billion; these figures should be treated as a range rather than a precise institutional consensus. (marketbeat.com)
The prior-year comparison is not easy. Fiscal Q1 2026 delivered 8% constant-currency organic growth, including 8% in Healthcare, 10% in AST and 4% in Life Sciences. (sterisplc.gcs-web.com)
AST is STERIS’s highest-margin segment and therefore has an outsized effect on earnings. But it enters the quarter facing:
STERIS has guided AST to 7%–8% organic growth for the full year, but management previously described an expected cadence of slower growth in the first half, followed by acceleration in Q3 and easier comparisons in Q4. (investing.com)
What would be encouraging: AST service growth in the mid- to high-single digits, stable pricing and commentary that customer inventory reductions are ending.
What would be concerning: Low-single-digit or negative service-volume growth accompanied by a less confident second-half recovery narrative. Because AST has segment margins above 40%, weakness here would be more consequential than an equivalent revenue miss elsewhere.
Healthcare represents approximately 70% of company revenue and is supported by recurring service and consumables demand tied to procedure volumes. The business finished fiscal 2026 with:
The key question is whether Healthcare can sustain approximately 6%–7% organic growth despite a somewhat tougher comparison. Investors should separate the segment’s components:
Two recent tuck-in acquisitions—the MEDglas supplier integration and a portfolio of GI products—are expected to add approximately $45 million of FY2027 revenue, or nearly one percentage point to Healthcare’s reported growth. Investors should avoid interpreting acquisition-supported reported growth as purely organic execution.
STERIS expects roughly 50 basis points of full-year EBIT-margin expansion at the top end of guidance. The major moving pieces are:
Tailwinds
Headwinds
Management is assuming tariffs are approximately flat year over year and has not included tariff refunds in guidance. (fool.com)
A revenue beat driven by lower-margin capital equipment or acquisitions would therefore be less valuable than a smaller beat driven by AST service, Healthcare consumables and pricing. Investors should focus on gross margin, adjusted EBIT margin and segment operating margins, not just consolidated sales.
STERIS expects an approximately 25% adjusted effective tax rate in fiscal 2027, versus 24.4% in fiscal 2026 and 23.5% in the prior-year first quarter. The increase reflects geographic profit mix and withholding taxes associated with moving cash across borders for dividends, acquisitions and repurchases. (sterisplc.gcs-web.com)
This means operating-income growth may not translate one-for-one into adjusted-EPS growth. If EPS is only around consensus despite solid segment performance, investors should determine whether the difference is operational or simply tax-related.
The most likely outcome is an affirmation of FY2027 guidance. STERIS deliberately began the year with conservative AST assumptions, while Healthcare and Life Sciences entered the year with healthy underlying demand.
A guidance raise is possible but probably unnecessary after only one quarter. More important will be whether management:
The FY2027 free-cash-flow target is approximately 14% below fiscal 2026’s exceptional $983 million. That decline is primarily a normalization issue: working capital is expected to grow with volume, and the company faces additional incentive-compensation and settlement payments. It should not automatically be read as deterioration in earnings quality. (sterisplc.gcs-web.com)
STERIS finished fiscal 2026 with gross debt of approximately $1.9 billion and gross leverage near 1.2 times EBITDA, leaving substantial balance-sheet capacity.
The company has authorized up to $1 billion of share repurchases and intends to deploy roughly $200 million–$300 million annually, subject to cash availability and the withholding-tax cost of moving cash. (fool.com)
Questions worth monitoring include:
Buybacks should support per-share growth, but they are unlikely to transform near-term EPS because of the associated tax and financing friction.
This outcome would support the thesis that AST’s slowdown was temporary and that STERIS can return to double-digit EPS growth with improving margins.
This would represent satisfactory execution, although the stock reaction could be muted given the recent rally and roughly 21-times forward valuation.
The biggest risk would not be a modest Q1 miss by itself; it would be evidence that AST’s recovery is being pushed out while margin headwinds are proving more durable.
STERIS enters fiscal Q1 with a durable Healthcare franchise, improving Life Sciences demand and a strong balance sheet. The debate is concentrated in AST and margins.
A constructive report does not require a major guidance increase. It does require:
With the stock back near $233, investors are likely to reward quality and visibility more than a small headline beat. The cleanest bullish signal would be solid AST volume commentary combined with Healthcare recurring-revenue strength and unchanged—or better—full-year margin expectations.